Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors

Chow Laura Q. M.; Smith David C.; Tan Antoinette R.; Denlinger Crystal S.; Wang Ding; Shepard Dale R.; Chaudhary Archana; Lin Yong; Gao Ling

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors

【24h】

Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors

机译：晚期恶性实体瘤患者II期研究中雷莫西单抗与紫杉醇之间缺乏药代动力学药物相互作用

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The objective of this phase II study was to evaluate pharmacokinetic interaction potential between ramucirumab and paclitaxel in patients with advanced cancer.

机译：这项II期研究的目的是评估雷莫西单抗和紫杉醇在晚期癌症患者中的药代动力学相互作用潜力。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2016年第2期|共9页
作者
Chow Laura Q. M.; Smith David C.; Tan Antoinette R.; Denlinger Crystal S.; Wang Ding; Shepard Dale R.; Chaudhary Archana; Lin Yong; Gao Ling;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Ramucirumab; Paclitaxel; Pharmacokinetics; Drug-drug interactions; Cancer;

机译：雷米库单抗;紫杉醇;药代动力学;药物相互作用;癌症;

相似文献

外文文献
中文文献
专利

1. Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors [J] . Chow Laura Q. M., Smith David C., Tan Antoinette R., Cancer chemotherapy and pharmacology. . 2016,第2期

机译：晚期恶性实体瘤患者II期研究中雷莫西单抗与紫杉醇之间缺乏药代动力学药物相互作用
2. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors [J] . Jennifer R. Diamond, Benjamin Wu, Neeraj Agarwal, Investigational New Drugs . 2015,第3期

机译：血管生成素-1 /血管生成素-2抑制肽体曲巴尼单抗（AMG 386）和紫杉醇在晚期实体瘤患者中的药代动力学药物相互作用
3. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors [J] . Investigational new drugs. . 2015,第3期

机译：血管生成素-1 /血管生成素-2抑制肽体曲巴尼单抗（AMG 386）和紫杉醇在晚期实体瘤患者中的药代动力学药物相互作用
4. Pharmacokinetic studies of delta-aminolevulinic-acid-induced protoporphyrin IX build-up in some malignant tumors [C] . Katarina Svanberg, M.D., Lund Univ. Hospital, Advances in Laser and Light Spectroscopy to Diagnose Cancer and Other Diseases II . 1995

机译：δ-氨基乙酰丙酸诱导的原卟啉IX在某些恶性肿瘤中的药代动力学研究
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors [O] . Laura Q. M. Chow, David C. Smith, Antoinette R. Tan, -1

机译：在晚期恶性实体瘤患者的II期研究中拉莫昔单抗和紫杉醇之间缺乏药代动力学药物相互作用
7. Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors [O] . 2016

机译：在晚期恶性实体瘤患者的II期研究中，拉莫西鲁单抗和紫杉醇之间缺乏药代动力学药物相互作用

Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors

摘要

著录项

相似文献

相关主题

期刊订阅